Silence Therapeutics plc 8-K

What Happened
On May 7, 2026 Silence Therapeutics plc filed an 8-K (Item 2.02) to announce its results of operations and financial condition for the quarter ended March 31, 2026. The company furnished a press release with those quarterly results and recent business highlights as Exhibit 99.1 to the report. The filing was signed by Iain Ross, Interim Principal Executive Officer and Chairman of the Board.

Key Details

• Reporting period: quarter ended March 31, 2026.
• Filing date / press release: May 7, 2026 (Exhibit 99.1).
• Form 8-K item: 2.02 (Results of Operations and Financial Condition); exhibit list also included Exhibit 104 (interactive XBRL).
• Signed by: Iain Ross, Interim Principal Executive Officer and Chairman.

Why It Matters
This 8-K provides the company’s latest quarterly results and business highlights; investors should review the attached press release (Exhibit 99.1) for the specific revenue, earnings, cash position, and operational updates. Timely disclosure of quarterly results can affect investor decisions and market reaction, so retail investors should read the press release and watch for any follow-up filings (e.g., quarterly reports) for full financial details and context.